These exceedingly low LRR rates suggests that investigation of RT omission may be warranted in patients with T1N0 HER2+ BC treated with upfront lumpectomy and adjuvant trastuzumab-based systemic therapy. This evidence concerns the gene ERBB2 and breast cancer.